What is the efficacy and role of capmatinib?

Capmatinib (Capmatinib) is a selective c-MET kinase inhibitor. The main effect of capmatinib is to inhibit the activity of c-MET kinase. It is a potent and selective c-MET kinase inhibitor with an average IC50 of 0.13 nM, showing strong inhibitory ability. Capmatinib can effectively inhibit the proliferation and migration of c-MET-dependent tumor cells and induce cell apoptosis, showing significant anti-tumor activity. The drug is specifically targeted at adults with metastatic non-small cell lung cancer caused by MET exon 14 skipping mutations. Additionally, it inhibits the growth of cancer cells driven by mutant MET variants lacking exon 14.

Capmatinib interacts withHGF, MET and other pathways to induce MET phosphorylation and affect the expression of its downstream target genes. This further affects the proliferation and survival of MET-dependent tumor cells. Clinical studies have shown that capmatinib can significantly inhibit tumor proliferation and induce tumor cell apoptosis.

In a Phase II clinical studyCapmatinib showed significant efficacy in patients with non-small cell lung cancer with METex14 skipping mutations. For previously treated patients, the overall response rate (ORR) was 41% and the median response time was 9.7 months; for treatment-naive patients, the ORR was as high as 68% and the median response time was 12.6 months. These data fully demonstrate the therapeutic efficacy of capmatinib.

However, like other medications, capmatinib may cause some side effects. Common ones include systemic reactions (such as edema, fatigue, etc.), gastrointestinal reactions (such as nausea, vomiting, etc.), respiratory system reactions, skin and nervous system reactions, etc. Despite these side effects, capmatinib is generally safe and effective.

In general, capmatinib, as a new type of targeted therapy, provides a new treatment option for patients with non-small cell lung cancer, especially those with cancer caused byMET gene mutations.